This mutant, Survivin-T34A, was found to significantly increase apoptosis in the pancreatic cancer cell line, suggesting that it could be used to treat pancreatic cancer (Aspe et al., 2014). This evidence concerns the gene BIRC5 and pancreatic neoplasm.